Antibody–drug conjugates for targeted anticancer drug delivery

Abstract

Antibody–drug conjugates (ADCs) are tumor-targeted therapeutic agents that combine the specificity of monoclonal antibodies (mAbs) with the potent anti-tumor effects of cytotoxic drugs. Over the past few years, ADCs have become a powerful tool in the field of cancer chemotherapy. Recently, two ADC products, brentuximab vedotin (Adcetris®) and trastuzumab… (More)
DOI: 10.1007/s40005-016-0254-z

Topics

4 Figures and Tables

Slides referencing similar topics